Pharmaceuticals company Anthem Biosciences announced Q1FY26 results Consolidated Revenue from Operations was Rs 5,402 million for the quarter. CRDMO business delivered Rs 4,527 million revenues. Specialty Ingredients delivered Rs 875 million revenues. EBITDA was Rs 2,143 million, with EBITDA margins at 38%. PAT (Profit After Tax)was Rs 1,358 million, with PAT margins at 24%. Net Cash position as of June 30, 2025, is Rs 7,848 million. Ajay Bhardwaj, Chairman, Managing Director & CEO, Anthem Biosciences, said: “We have kicked off FY26 with a strong performance, laying a solid foundation for the year ahead. Strong YoY growth in Q1FY26 reflects a CRDMO revenue stream that started ramping up since Q2FY25. A combination of a dedicated team, strategic focus, operational excellenceand long-standing client partnerships has helped us deliver performance across both CRDMO and Specialty Ingredients business”. Result PDF